Translational interventional cardiology: a new editorial priority for EuroIntervention by Khamis, RY et al.
E D I T O R I A L
The opinions expressed in this article are not necessarily those of the Editors of EuroIntervention or 
of the European Association of Percutaneous Cardiovascular Interventions.
EuroIntervention 2
0
16
;1
2
:0
-0   
D
O
I: 10
.4
2
4
4
/E
IJV1
2
I1
A
?
1
© Europa Digital & Publishing 2016. All rights reserved.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
*Corresponding author: National Heart and Lung Institute. 5th Floor, ICTEM, Hammersmith Hospital Campus. Imperial 
College London.  Du Cane Road. W12 0HN. London, United Kingdon. E-mail: r.khamis@imperial.ac.uk
Translational interventional cardiology: a new editorial 
priority for EuroIntervention
Ramzi Y. Khamis*, MB ChB, PhD, MRCP, FESC; Dorian O. Haskard, DM, FRCP, FMedSci; 
Patrick W. Serruys, MD, PhD, FESC
National Heart and Lung Institute, Imperial College London, London, United Kingdom
William Harvey published his seminal work in 1628, in book form, 
entitled “Exercitatio Anatomica de Motu Cordis et Sanguinis in 
Animalibus” (Latin for “An anatomical exercise on the motion of 
the heart and blood in living beings”)1. Nearly a hundred years 
later, in 1711, Stephen Hales performed right and left heart cath-
eterisation on a horse. Almost 250 years after that, in 1958, Mason 
Sones inadvertently injected contrast into a right coronary artery 
whilst performing cardiac catheterisation and interventional cardi-
ology was born2. This translational route took 300 years, is still in 
development and likely to be so for as long as humans have coro-
nary arteries. The way this development is evolving, not only lon-
gitudinally, but also widening in its breadth has been captivating. 
Interventional cardiology no longer relies just on understanding 
the anatomy and physiology of circulation, but also on under-
standing the many components of human biology that contribute 
to vascular health and disease. Thus, linking inflammation and 
genomics to the physiology of the circulation, molecular pathol-
ogy of atherosclerosis and development of new technologies are at 
the centre of this rapidly evolving field3. What has become quite 
clear is that the gap between the many “basic science” disciplines 
involved and clinical application is narrowing both significantly 
and rapidly.
Early scientific research that may be aimed at translation often 
takes many years to evolve, with endless problem solving that 
often requires the researchers to adapt and sometimes start afresh 
when an idea fails. However, it is in the interest of the wider 
research community, as well as the clinical community, to support 
these early stage endeavours and engage with them at an embry-
onic stage.
As the world changes, and globalisation takes medical research 
to astronomical heights, the need for “translational medicine” has 
become a de facto one. This field brings those working in basic 
research closer to those undertaking clinical research and the gen-
eral community of clinicians. It encompasses a broad spectrum 
of research foci. The main categories of translational research 
are those that encompass early-stage work from basic discov-
eries of new molecules, animal models and new devices all the 
way through to first-in-man, phase 1 and phase 2 studies. This is 
referred to as T1 translational research. The second part of trans-
lational medicine (T2) involves the implementation of clinical 
trial results in clinical practice. The third aspect, termed (T3), is 
research that promotes a dynamic interaction between laboratory-
based science and population-based research in both directions. 
T3 is very interesting for us as interventionists, as it encourages 
a two-way stream between observations obtained either in the 
catheter laboratory or from clinical interventional studies, back to 
the science laboratory and vice versa4.
Furthermore, the all-encompassing umbrella of translational 
medicine, with all its challenges, requires the collaboration of 
many disciplines and a shared vision. Often, research is a collabo-
ration among basic scientists, clinicians, engineers and industry 
partners. The need for partnership from non-commercial grant-
funding bodies as well as industry is crucial5,6.
Within interventional cardiology, there is now a virtual explo-
sion of novel and exciting ideas, with much early work that needs 
to be cultivated and critically appraised. The field is rich with 
device development, new molecules, and new concepts that are 
yet to be explored at a therapeutic level. Yet it seems that the “job-
bing” cardiologist is pretty much deprived from taking a “peek” 
at this work in the mainstream cardiology journals. It is well rec-
ognised that discussion and interaction among basic scientists, 
bioengineers, translational cardiologists and the interventional 
community at large hardly ever seem to take place in a unified 
environment.
A significant obstacle for those undertaking translational work, 
in a research world that is rightly or wrongly judged by standard-
ised units such as impact factor, is that their work may be over-
looked by those journals only seeking high-impact publications. 
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The difficulty in publishing translational work has historically been 
due to the conundrum of it not falling within “a basic science remit” 
or a “clinical trial remit”. Therefore, work that explores novel tar-
gets, models, and devices in early animal studies that lacks detailed 
mechanistic data tends to be excluded from high-impact basic sci-
ence journals. Similarly, first-in-man studies or phase 1 and 2 stud-
ies can be largely ignored by mainstream clinical journals7.
Grant-funding bodies, such as the UK-based Wellcome Trust 
and the British Heart Foundation, now encourage translational 
research and offer dedicated funding as well as training streams 
for it. However, besides the need for funding and institutional sup-
port for translational interventional cardiology, there is a real need 
for a forum where the work is exposed to the general commu-
nity and given due attention. Recently, general cardiology jour-
nals have identified the gap and there have been some efforts to 
develop new publications that expose translational work8 and alter 
the focus from impact factor to translational impact7.
EuroIntervention has traditionally published both experi-
mental and preclinical papers in the past and continues to do 
so (Figure 1). In order to structure the future in line with the 
international push to focus on translational medicine, I (RK) 
have accepted the honourable invitation to take up the position 
of Translational Research Editor for the Journal. We will aim to 
welcome translational work that is judged by the editors to have 
a reasonable “translational impact”. We will not be shy in tak-
ing some risk on some of the work, to allow it an opportunity 
to flourish and be given adequate attention by the wider com-
munity at an early stage. We hope that the input and interaction 
from our audience will ease the route to clinical implementation 
of important ideas that have undergone rigorous study in transla-
tional models and early human studies.
In this issue of EuroIntervention, Schmitt et al present their pio-
neering translational interventional work testing a stent-mounted, 
fully tissue-engineered heart valve in an ovine model9. These valves 
are grown in the laboratory (this word can foster misunderstand-
ing between scientists and clinicians – I refer here to the “science 
laboratory” rather than the “catheter laboratory”!), and are made 
from ovine vascular-derived cells. The valves are decellularised to 
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Figure 1. Preclinical/experimental research submissions in 
EuroIntervention.
reduce any immunogenic reactions when implanted, and sterilised 
prior to implantation via the transcatheter route in the pulmonary 
position. The bioengineering novelty is in complete endothelialisa-
tion and remodelling of the valvular matrix, with the valve being 
quickly populated by the recipient’s autologous cells. Although the 
results show worsening regurgitation over time, probably due to 
technical tissue engineering issues and adaptation to the ovality of 
the valve when implanted, the authors eloquently describe these 
challenges and offer explanations. Clearly, the current version of 
this valve is still in need of significant development prior to first-
in-man study, but the research is innovative and has been long 
awaited by the structural interventional community. Therefore, 
there is a real prospect that this approach will have a long-stand-
ing impact on the future of transcatheter valve interventions. We 
really hope that you will be pleased to see this innovation featured 
in this issue of EuroIntervention.
Conflict of interest statement
The authors have no conflicts of interest to declare.
References
 1. Packard FR. Harvey and the tercentenary celebration of his 
book “De motu cordis et sanguinis hominis”, by the Royal College 
of Physicians of London. Bull Med Libr Assoc. 1929;18:5-14.
 2. Mueller RL, Sanborn TA. The history of interventional cardi-
ology: cardiac catheterization, angioplasty, and related interven-
tions. Am Heart J. 1995;129:146-72.
 3. Gleissner CA. Translational atherosclerosis research: From 
experimental models to coronary artery disease in humans. 
Atherosclerosis. 2016;248:110-6.
 4. Rubio DM, Schoenbaum EE, Lee LS, Schteingart DE, 
Marantz PR, Anderson KE, Platt LD, Baez A, Esposito K. Defining 
translational research: implications for training. Acad Med. 
2010;85:470-5.
 5. Mankoff SP, Brander C, Ferrone S, Marincola FM. Lost in 
Translation: Obstacles to Translational Medicine. J Transl Med. 
2004;2:14.
 6. Lauer MS, Skarlatos S. Translational research for cardiovas-
cular diseases at the National Heart, Lung, and Blood Institute: 
moving from bench to bedside and from bedside to community. 
Circulation. 2010;121:929-33.
 7. Mann DL, Annex BH, Bishopric NH, Force T, Kelly DP, 
Libby P, Roberts R, van Rooij E, Tomaselli G, Newby LK. 
Introducing JACC: Basic to Translational Science. Why Now? JACC. 
2016;1:1-2.
 8. Hall JL, Dib N. Letter from the editors. J Cardiovasc Transl 
Res. 2008;1:1-2.
 9. Schmitt B, Spriestersbach H, O h-Icí D, Radtke T, Bartosch M, 
Peters H, Sigler M, Frese L, Dijkman PE, Baaijens FPT, 
Hoerstrup SP, Berger F. Percutaneous pulmonary valve replace-
ment using completely tissue-engineered off-the-shelf heart valves: 
six months in vivo functionality and matrix remodelling in sheep. 
EuroIntervention. 2016;12:???
